Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped

More documents

Recommendations

Info

Pooled results 100% Time to PSA progression (50% increase) 100% Overall survival 75% 50% HR=1.6 75% 50% HR=1.08 25% Castration Casodex 0% 0 1 2 3 4 Time (years) 665/2094 (31.8%) progressed Median : 19 and 30 months (24.9) 25% 0% Castration Casodex 0 1 2 3 4 Time (years) 1143 / 2161 (52.9%) died Median: 26 and 28 months 5
PSA data (M1) Mean log(PSA) -2 0 2 4 6 Association between PSA longitudinal changes and hazard of death R²(t) >= 0.90 at any time from m7 0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180 192 Week
Page 1 and 2: EORTC Surrogacy Case Study: Prostat
Page 3 and 4: Prostate Specific Antigen (PSA) •
Page 5 and 6: Transition between clinical states
Page 7 and 8: Surrogate endpoint • An outcome m
Page 9 and 10: Meta-analytic validation First stag
Page 11 and 12: PSA - defined endpoints in prostate
Page 13 and 14: PSA “surrogacy” studies in the
Page 15 and 16: Published PSA surrogacy studies Col
Page 17 and 18: Review • 2 meta-analytic validati
Page 19: PSA endpoints PSA normalization A P
Page 23 and 24: Treatment effects on OS against tre
Page 25 and 26: Prediction for a new trial - M1 •
Page 27 and 28: PSA doubling-free survival (PSA-D)
Page 29 and 30: Recommendation, M1 hormone sensitiv
Page 31 and 32: 4m vs 24m ADT adjuvant to irradiati
Page 33 and 34: PSA-DT and TTBF surrogate for PCa-s
Page 35 and 36: PSA response or PSA-V surrogate for
Page 37 and 38: Of interest… The search for the g
Page 39 and 40: Conclusions for HRPC on chemotherap
Page 41 and 42: ASCENT trial High dose Calcitriol (
Page 43 and 44: Be aware of your drug’s effect on

Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?